Anika Therapeutics, Inc. (FRA:AKP)

Market Cap	112.04M -50.9%
Revenue (ttm)	96.14M +30.6%
Net Income	-28.16M
EPS	-1.95
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	40
Open	7.45
Previous Close	7.30
Day's Range	7.45 - 7.45
52-Week Range	6.90 - 17.30
Beta	n/a
RSI	33.52
Earnings Date	Mar 9, 2026

About Anika Therapeutics

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1983
• Employees: 288
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: AKP

Financial Performance

In 2024, Anika Therapeutics's revenue was $119.91 million, a decrease of -0.73% compared to the previous year's $120.79 million. Losses were -$56.39 million, -31.79% less than in 2023.

Financial numbers in USD